Home/Filings/4/0001209191-22-023656
4//SEC Filing

Turner William D. 4

Accession 0001209191-22-023656

CIK 0001290149other

Filed

Apr 6, 8:00 PM ET

Accepted

Apr 7, 4:12 PM ET

Size

14.5 KB

Accession

0001209191-22-023656

Insider Transaction Report

Form 4
Period: 2022-04-05
Turner William D.
Chief Reg & Tech Ops Officer
Transactions
  • Sale

    Common Stock

    2022-04-05$37.09/sh100$3,7090 total
  • Exercise/Conversion

    Common Stock

    2022-04-06$12.05/sh+6,347$76,4816,347 total
  • Sale

    Common Stock

    2022-04-06$37.25/sh6,347$236,4090 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2022-04-05+1000 total
    Exercise: $12.05Exp: 2030-08-04Common Stock (100 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2022-04-06+6,3470 total
    Exercise: $12.05Exp: 2030-08-04Common Stock (6,347 underlying)
  • Exercise/Conversion

    Common Stock

    2022-04-05$12.05/sh+100$1,205100 total
Footnotes (2)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2021. The Reporting Person is subject to a Lock-Up Letter Agreement that expires on April 26, 2022. The sale of shares is a permissible exemption under the terms of the Lock-Up Letter Agreement.
  • [F2]On August 4, 2021, the option vested as to 25% of the total shares granted on August 4, 2020, with the remaining shares from that grant vesting in equal monthly installments over the following 36 months, with 100% of the total shares vested on August 4, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Issuer

Sierra Oncology, Inc.

CIK 0001290149

Entity typeother

Related Parties

1
  • filerCIK 0001819688

Filing Metadata

Form type
4
Filed
Apr 6, 8:00 PM ET
Accepted
Apr 7, 4:12 PM ET
Size
14.5 KB